<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Wuxi Biologics — News on 6ix</title>
<link>https://6ix.com/company/wuxi-biologics</link>
<description>Latest news and press releases for Wuxi Biologics on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 06:14:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/wuxi-biologics" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836880578dffbe2df16b1d3.webp</url>
<title>Wuxi Biologics</title>
<link>https://6ix.com/company/wuxi-biologics</link>
</image>
<item>
<title>WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-receives-south-korea-mfds-gmp-certification-to-enable-commercial-manufacturing-of-bispecific-antibody-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-receives-south-korea-mfds-gmp-certification-to-enable-commercial-manufacturing-of-bispecific-antibody-therapeutics</guid>
<pubDate>Thu, 23 Apr 2026 06:14:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug Product Packaging Center (DPPC) – have received GMP certification from South Korea Ministry of Food and Drug Safety (MFDS). The certification positions WuXi Biologics to provide end‑to‑end commercial manufacturing services, covering both drug subst</description>
</item>
<item>
<title>WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-recognized-by-morningstar-sustainalytics-as-industry-and-regional-esg-leader-for-sixth-year</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-recognized-by-morningstar-sustainalytics-as-industry-and-regional-esg-leader-for-sixth-year</guid>
<pubDate>Fri, 17 Apr 2026 05:30:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026.</description>
</item>
<item>
<title>WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-achieves-iso-13485-certification-signifying-strong-capabilities-in-drug-device-combination-product-development-and-manufacturing</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-achieves-iso-13485-certification-signifying-strong-capabilities-in-drug-device-combination-product-development-and-manufacturing</guid>
<pubDate>Wed, 15 Apr 2026 02:39:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully achieved ISO 13485:2016 Medical Device Quality Management System certification with zero non-conformities, becoming among the first in China's drug-device combination products sector to obtain this certification. The achievement highlights the company's robust quality system and strong compliance capabilities, reflecting a solid foundation for deliv</description>
</item>
<item>
<title>WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-honored-with-cdmo-leadership-awards-for-ninth-consecutive-year</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-honored-with-cdmo-leadership-awards-for-ninth-consecutive-year</guid>
<pubDate>Mon, 30 Mar 2026 05:33:00 GMT</pubDate>
<description>WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best Analytical Services", "Best Overall Staff", and "Best Project Management". These achievements mark WuXi Biologics' ninth c</description>
</item>
<item>
<title>WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-reports-record-2025-annual-results-operational-excellence-driven-by-digital-native-architecture</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-reports-record-2025-annual-results-operational-excellence-driven-by-digital-native-architecture</guid>
<pubDate>Wed, 25 Mar 2026 10:22:00 GMT</pubDate>
<description>WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. The company reported a 16.7% increase in revenue, an IFRS gross profit growth of 30.9%, a 5 percentage-point expansion to 46.0% in gross profit margin and adjusted gross profit surged by25.5% year-on-year. The strong profitable growth has been dr</description>
</item>
<item>
<title>WuXi Biologics Reports Record 2025 Annual Results</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-reports-record-2025-annual-results</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-reports-record-2025-annual-results</guid>
<pubDate>Tue, 24 Mar 2026 11:44:00 GMT</pubDate>
<description>WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development and manufacturing, today announced audited results for the year ended December 31, 2025 ("Reporting Period").</description>
</item>
<item>
<title>World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target</title>
<link>https://6ix.com/company/wuxi-biologics/news/world-water-day-wuxi-biologics-advances-water-stewardship-and-achieves-water-target</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/world-water-day-wuxi-biologics-advances-water-stewardship-and-achieves-water-target</guid>
<pubDate>Sun, 22 Mar 2026 01:30:00 GMT</pubDate>
<description>On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impact.</description>
</item>
<item>
<title>WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-wins-multiple-asia-pacific-biopharma-excellence-awards-for-leadership-in-bioprocessing-manufacturing-excellence-and-digital-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-wins-multiple-asia-pacific-biopharma-excellence-awards-for-leadership-in-bioprocessing-manufacturing-excellence-and-digital-innovation</guid>
<pubDate>Fri, 13 Mar 2026 03:09:00 GMT</pubDate>
<description>WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excellence Awards (ABEA), achieving a historic record for the most accolades received in a single year. These recognitions underscore the company's sustained leadership in end‑to‑end biologics development and manufacturing capabilities, digital innovat</description>
</item>
<item>
<title>Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs</title>
<link>https://6ix.com/company/wuxi-biologics/news/earendil-labs-and-wuxi-biologics-enter-strategic-collaboration-to-accelerate-development-and-manufacturing-of-bispecificmultispecific-antibodies-and-adcs</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/earendil-labs-and-wuxi-biologics-enter-strategic-collaboration-to-accelerate-development-and-manufacturing-of-bispecificmultispecific-antibodies-and-adcs</guid>
<pubDate>Thu, 12 Mar 2026 09:00:00 GMT</pubDate>
<description>Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today jointly announced the signing of a strategic collaboration agreement on the development and manufacturing of multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs' pipeline targeting autoimmune disease, cancer, and other diseas</description>
</item>
<item>
<title>WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-included-in-sandp-global-sustainability-yearbook-for-fourth-consecutive-year</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-included-in-sandp-global-sustainability-yearbook-for-fourth-consecutive-year</guid>
<pubDate>Mon, 02 Mar 2026 03:21:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025 Corporate Sustainability Assessment (CSA). The company was ranked top in its industry and achieved a Top 1% S&P Global CSA Score, marking the fourth consecutive year that WuXi Biologics has received this highest level of distinction.</description>
</item>
<item>
<title>WuXi Vaccines Receives Brazil's ANVISA GMP Certification</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-vaccines-receives-brazils-anvisa-gmp-certification</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-vaccines-receives-brazils-anvisa-gmp-certification</guid>
<pubDate>Thu, 12 Feb 2026 03:48:00 GMT</pubDate>
<description>WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and finish facility (DP17) in Suzhou from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The facility is providing integrated manufacturing services for Instituto Butantan's dengue vaccine (Butantan-DV) production project.</description>
</item>
<item>
<title>WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-awarded-ecovadis-platinum-023000975</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-awarded-ecovadis-platinum-023000975</guid>
<pubDate>Mon, 09 Feb 2026 02:30:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the third year the company has received the rating's highest level of recognition.</description>
</item>
<item>
<title>WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-vertex-sign-license-030800504</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-vertex-sign-license-030800504</guid>
<pubDate>Tue, 03 Feb 2026 03:08:00 GMT</pubDate>
<description>WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.</description>
</item>
<item>
<title>WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-sinorda-biomedicine-enter-023900304</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-sinorda-biomedicine-enter-023900304</guid>
<pubDate>Thu, 29 Jan 2026 02:39:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases.</description>
</item>
<item>
<title>WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-hanchorbio-enter-strategic-093500364</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-hanchorbio-enter-strategic-093500364</guid>
<pubDate>Mon, 26 Jan 2026 09:35:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio's pipeline.</description>
</item>
<item>
<title>HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline</title>
<link>https://6ix.com/company/wuxi-biologics/news/hanchorbio-and-wuxi-biologics-enter-strategic-partnership-to-advance-next-generation-bi-and-multi-functional-fusion-protein-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/hanchorbio-and-wuxi-biologics-enter-strategic-partnership-to-advance-next-generation-bi-and-multi-functional-fusion-protein-pipeline</guid>
<pubDate>Mon, 26 Jan 2026 07:00:00 GMT</pubDate>
<description>HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio's pipeline.</description>
</item>
<item>
<title>JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth</title>
<link>https://6ix.com/company/wuxi-biologics/news/jpm-highlights-or-wuxi-biologics-ceo-dr-chris-chen-scaled-crdmo-platform-delivering-sustainable-high-growth</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/jpm-highlights-or-wuxi-biologics-ceo-dr-chris-chen-scaled-crdmo-platform-delivering-sustainable-high-growth</guid>
<pubDate>Thu, 15 Jan 2026 04:00:00 GMT</pubDate>
<description>On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, highlighting the company's 2025 achievements and outlining its outlook.</description>
</item>
<item>
<title>WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-obtains-gmp-certification-030600705</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-obtains-gmp-certification-030600705</guid>
<pubDate>Tue, 13 Jan 2026 03:06:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have received GMP certifications from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for commercial manufacturing of an ophthalmic biologic. WuXi Biologics delivers end-to-end manufacturing services for this ophthalmic biologic, cove</description>
</item>
<item>
<title>WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-launches-industry-leading-130900424</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-launches-industry-leading-130900424</guid>
<pubDate>Mon, 12 Jan 2026 13:09:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufacturing. By combining advanced real-time process monitoring with Raman-based Process Analytical Technology (PAT) and predictive in-silico modeling, PatroLab™ enables real-time and smarter analytics, proactive control, and accelerated decision-maki</description>
</item>
<item>
<title>WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement</title>
<link>https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-achieves-iso-20400-certification-setting-benchmark-in-sustainable-procurement</link>
<guid isPermaLink="true">https://6ix.com/company/wuxi-biologics/news/wuxi-biologics-achieves-iso-20400-certification-setting-benchmark-in-sustainable-procurement</guid>
<pubDate>Mon, 05 Jan 2026 03:57:00 GMT</pubDate>
<description>WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility across the supply chain. This recognition highlights WuXi Biologics' outstanding performance in sustainability and showcases the company's dedicated efforts in strengthening supply chain resilience.</description>
</item>
</channel>
</rss>